UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

Journal of clinical oncology, 1993-12, Vol.11 (12), p.2405-2410

1993

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

Journal of clinical oncology, 1995-08, Vol.13 (8), p.2056-2065

1995

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

Investigational new drugs, 2004-08, Vol.22 (3), p.263-275

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1185-1191

1996

Link zum Volltext

Verfügbarkeit prüfen

Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor

JNCI : Journal of the National Cancer Institute, 1995-09, Vol.87 (17), p.1316-1322

1995

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.478-484

1999

Link zum Volltext

Verfügbarkeit prüfen

Successful re-treatment with taxol after major hypersensitivity reactions

Journal of clinical oncology, 1993-05, Vol.11 (5), p.885-890

1993

Link zum Volltext

Verfügbarkeit prüfen

Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y–Expressing Epithelial Tumors

Journal of clinical oncology, 2000-06, Vol.18 (11), p.2282-2292

2000

Link zum Volltext

Verfügbarkeit prüfen

Extra hematopoietic effect of colony-stimulating factors [letter; comment]

Blood, 1989-09, Vol.74 (4), p.1446-1447

Onetto, N

1989

Link zum Volltext

Verfügbarkeit prüfen

Overview of Taxol safety

Journal of the National Cancer Institute. Monographs, 1993 (15), p.131

1993

Link zum Volltext

Verfügbarkeit prüfen

Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer

Seminars in oncology, 1995-08, Vol.22 (4 Suppl 8), p.33

1995

Link zum Volltext

Verfügbarkeit prüfen

Current dosage and schedule issues in the development of paclitaxel (Taxol)

Seminars in oncology, 1993-08, Vol.20 (4 Suppl 3), p.31

1993

Link zum Volltext

Verfügbarkeit prüfen

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

Journal of clinical oncology, 1994-12, Vol.12 (12), p.2654-2666

1994

Link zum Volltext

Verfügbarkeit prüfen

Taxol: the first of the taxanes, an important new class of antitumor agents

Seminars in oncology, 1992-12, Vol.19 (6), p.646

1992

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer : A study of the National Cancer Institute of Canada Clinical Trials Group

Annals of oncology, 1996-12, Vol.7 (10), p.1077-1079

1996

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil

Journal of clinical oncology, 1993-12, Vol.11 (12), p.2411-2416

1993

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

Journal of clinical oncology, 1995-05, Vol.13 (5), p.1152-1159

1995

Link zum Volltext

Verfügbarkeit prüfen

Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer

The New England journal of medicine, 1991-06, Vol.324 (25), p.1773-1778

1991

Link zum Volltext

Verfügbarkeit prüfen

Phase I Clinical Trial of Recombinant Human Interleukin-3 Combined With Carboplatin in the Treatment of Patients With Recurrent Ovarian Carcinoma

JNCI : Journal of the National Cancer Institute, 1993-05, Vol.85 (10), p.823-825

1993

Link zum Volltext

Verfügbarkeit prüfen

P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?

Lung cancer (Amsterdam, Netherlands), 2005-07, Vol.49, p.S368-S368

2005

Link zum Volltext

Verfügbarkeit prüfen

EXTRA HEMATOPOIETIC EFFECT OF COLONY-STIMULATING FACTORS

Blood, 1989-09, Vol.74 (4), p.1446-1446

ONETTO, NICOLE

1989

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Granulocyte-Macrophage Colony-Stimulating Factor Receptor on the Blast Cells of Acute Myeloblastic Leukemia

Blood, 1990-01, Vol.75 (1), p.59-66

1990

Link zum Volltext

Verfügbarkeit prüfen

Tumor necrosis factor α stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte/macrophage colony-stimulating factor

The Journal of experimental medicine, 1989-07, Vol.170 (1), p.15-26

1989

Link zum Volltext

Verfügbarkeit prüfen

Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease

Biotechnology therapeutics, 1994, Vol.5 (1-2), p.1

1994

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(59)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(40)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Biological And Medical Sciences
(23)
Female
(23)
Adult
(20)
Medical Sciences
(20)
Oncology
(20)
Middle Aged
(18)
Pharmacology. Drug Treatments
(18)
Antineoplastic Agents
(17)
Aged
(14)
Chemotherapy
(14)
Paclitaxel - Adverse Effects
(10)
Paclitaxel - Administration & Dosage
(9)
Breast Neoplasms - Drug Therapy
(8)
Hematology
(8)
Adolescent
(7)
Child
(6)
Dose-Response Relationship, Drug
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

Quality of Life in Phase II Trials: a Study of Methodology and Predictive Value in Patients With Advanced Breast Cancer Treated With Paclitaxel Plus Granulocyte Colony-Stimulating Factor

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Successful re-treatment with taxol after major hypersensitivity reactions

Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y–Expressing Epithelial Tumors

Extra hematopoietic effect of colony-stimulating factors [letter; comment]

Overview of Taxol safety

Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer

Current dosage and schedule issues in the development of paclitaxel (Taxol)

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

Taxol: the first of the taxanes, an important new class of antitumor agents

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer : A study of the National Cancer Institute of Canada Clinical Trials Group

Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid Cancer

Phase I Clinical Trial of Recombinant Human Interleukin-3 Combined With Carboplatin in the Treatment of Patients With Recurrent Ovarian Carcinoma

P-946 Why do non smokers with non-small cell lung cancer (NSCLC) who receive erlotinib have better clinical outcomes than smokers?

EXTRA HEMATOPOIETIC EFFECT OF COLONY-STIMULATING FACTORS

Characterization of Granulocyte-Macrophage Colony-Stimulating Factor Receptor on the Blast Cells of Acute Myeloblastic Leukemia

Tumor necrosis factor α stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte/macrophage colony-stimulating factor

Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease

Long-Term Follow-up of a Phase III Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor After Autologous Bone Marrow Transplantation for Lymphoid Malignancies

Suchergebnisse filtern